Groucho proteins are transcriptional corepressors that are recruited to gene regulatory regions by numerous transcription factors. Long isoforms, such as Grg1, have all the domains of the prototype Drosophila Groucho. Short Groucho proteins, such as Grg5, have only the amino-terminal Q and G/P domains. We generated Grg1 and Grg5 transgenic mice and found that Grg1 overexpression induces lung adenocarcinoma, whereas Grg5 overexpression does not. Coexpression of Grg5 with Grg1 reduces tumor burden. Grg1 and Grg5 both diminish p53 protein levels; however, only Grg1 overexpression induces elevated levels of ErbB1 and ErbB2 receptor tyrosine kinases. The molecular and biological changes that accompany tumor progression in Grg1 transgenic mice closely reiterate events seen in human lung cancer. We also found that within a human lung tumor tissue array, a significant number of carcinomas overexpress Grg1/TLE1. Our data suggest that Grg1 overexpression contributes to malignancy in human lung cancers. (Cancer Res 2006; 66(3): 1294-301) 
Introduction
Human lung cancer is frequently associated with activation of oncogenes, such as K-ras, MYC, ErbB1, and ErbB2, and loss of tumor-suppressor genes, such as p53, Rb, and p16
INK4A (1, 2) . Some of these aberrations have been modeled in mice using transgenic and gene knockout strategies. Based on the high incidence of K-ras mutations in human lung adenocarcinoma, transgenic mice that express activated K-ras were generated (3) (4) (5) (6) . The K-ras-expressing mice develop lung tumors resembling human papillary adenocarcinoma. Loss of heterozygosity at 17p, the tp53 locus, correlates with tumor progression in human non-small cell lung cancer (NSCLC; ref. 7) . Likewise, loss of p53 accelerates lung tumorigenesis in the mutant K-ras transgenic mice (3, 5) . These animal models have validated the roles of K-ras and p53 gene mutations in lung cancer pathogenesis and represent valuable tools to study genetic modifiers and test therapeutic strategies. A significant number of lung tumors, however, do not harbor K-ras and/or p53 mutations.
This investigation reports the use of a novel Cre/loxP-based system for the generation of conditional transgenic mice. The system is based on the Z/AP Cre reporter (8) and through crosses with different Cre recombinase transgenic lines, it allows the generation of mice with either widespread or tissue-specific transgene expression. We made use of this system to overexpress Groucho-related genes (Grg ) in the mouse. Groucho proteins are transcriptional corepressors that interact with a number of transcription factors, histone deacetylase complex (HDAC) molecules, and hypoacetylated histones (9) (10) (11) (12) (13) . The Groucho family of proteins is encoded by Grg1-6 in mouse (14) (15) (16) (17) (18) (19) . They are called transducin-like enhancer-of-split (TLE) genes in humans (20) . Two major protein isoforms have been characterized. Full-length Groucho proteins possess all the domains of the prototype Drosophila Groucho protein. Shorter isoforms, such as Grg5, and alternatively spliced variants, such as Grg1-S and Grg3b, encode only the amino-terminal Q domain and a G/P domain (17, 18, 21) . The Q domain is a tetramerization domain (22) and it has been suggested that the short Groucho proteins inhibit the activity of the long proteins by forming nonfunctional complexes (23) (24) (25) . The short Groucho proteins are not able to bind HDAC molecules (26) and in some cases have been shown to enhance, rather than repress, transcriptional activation (26, 27) . Despite these findings, amino-terminal enhancer of split, the human homologue of Grg5, has been shown to function as a transcriptional corepressor with the androgen receptor and p65 subunit of nuclear factor-nB (28, 29) . The function of short Groucho proteins may, therefore, be context dependent.
Here, we report that transgenic mice with widespread Grg1 overexpression specifically develop lung tumors starting at 1 month of age. Coexpression of Grg5 lowers Grg1-induced tumor burden, suggesting a mechanism that is sensitive to levels of long and short Groucho isoforms. Development of lung tumors in the Grg1-overexpressing mice is associated with altered status of p53 and up-regulation of the ErbB1 and ErbB2 receptor tyrosine kinases. Examination of the expression of TLE1, the human Grg1 homologue, on a human lung cancer tissue array revealed that TLE1 is overexpressed in a significant number of both squamous cell carcinomas and adenocarcinomas. Cumulatively, the results of this study show that Grg1 can act as an oncoprotein in the lung.
Materials and Methods
Construction of Grg1 and Grg5 conditional transgenic mice. The Cre-conditional expression vector iZ/AP was created to achieve controlled expression in transgenic mice. The iZ/AP vector is a modified version of the Z/AP reporter construct (8) in which the human alkaline phosphatase (hPLAP) coding sequence was replaced by an Internal Ribosomal Entry Site-hPLAP cassette (IRES-hPLAP). The Grg1 and Grg5 coding sequences were ligated to unique BglII/XhoI sites upstream of the IRES-hPLAP cassette to create the vectors iZ/AP-Grg1 and iZ/AP-Grg5. The R1 embryonic stem cell line was maintained essentially as described (30) . Following electroporation with iZ/AP-Grg1 and iZ/AP-Grg5 DNA, embryonic stem cells were selected in G418 and subjected to a screening strategy previously used to select single-copy embryonic stem cell clones with strong transgene expression (8, 31, 32) . Selected clones were used to make aggregation chimeras and males were mated to CD1 females to identify germ-line transmitters. Ubiquitous Cre-excision was achieved by crossing transgenic offspring to the pCX-NLS-Cre mouse line (33) .
Mouse genotyping. Mice were genotyped by either lacZ or hPLAP staining of ear punch tissue (8) or by Southern blot analysis. The probe for Southern analysis of the Grg transgenes was an XhoI/SacII-excised fragment of the iZ/AP vector that overlapped the 3V region of the IREShPLAP cassette. The probe for Southern analysis of the pCX-NLS-Cre transgene was a XhoI/BglII fragment from the Cre coding sequence. 32 Plabeled probes were created by random priming using the Megaprime DNA-labeling kit (Amersham Pharmacia Biotech, Oakville, Canada).
Quantitation of tumors. Lungs were dissected, fixed in 4% paraformaldehyde, and examined for the presence of tumors on the pleural surface under Â10 magnification. Serial sectioning of paraffin-embedded lungs was done to examine for tumors not visible on the pleural surface. Fivemicrometer sections were cut at 100 Am step intervals throughout the lungs and sections were stained with H&E. Sections were scanned for adenomatous/carcinomatous proliferation at Â10 magnification. Mice with at least one tumorous lesion found in serial sections were counted as tumor positive. For quantification, 10 serial sections of the left pulmonary lobe were scored. Statistical significance was measured using a t test.
Histoenzymological staining. Fixation and staining of tissues, tissue culture plates and frozen sections for h-galactosidase and alkaline phosphatase activity were essentially as described (8) . All slides of frozen sections were counterstained with Nuclear Fast Red (Sigma-Aldrich, Oakville, Canada).
Immunohistochemistry. Paraffin sections (4-5 Am) were incubated with a mouse monoclonal antibody specific to thyroid transcription factor-1 (TTF-1; 1:50, LabVision/NeoMarkers, Fremont, CA), a rabbit polyclonal antibody for cytokeratin, wide spectrum screening (1:800, DakoCytomation, Inc., Mississauga, Canada), a mouse monoclonal antibody specific to vimentin (1:600, Sigma-Aldrich), or a mouse monoclonal antibody for proliferating cell nuclear antigen (PCNA, 1:200, Zymed Laboratories, Inc., Burlington, Canada). Primary dilutions were made in blocking solution (5% normal goat serum and 1% bovine serum albumin in PBS) and incubation was at room temperature overnight. Sections were subsequently incubated with biotinylated secondary antibodies, avidin-biotin complex and 3,3V -diaminobenzidine (DAB, Vector Laboratories, Inc., Burlington, Canada). For TTF-1 and PCNA, nickel was added to the DAB solution to enhance black nuclear staining. Sections were counterstained with methyl green (TTF-1 and PCNA) or hematoxylin (cytokeratin and vimentin).
In situ hybridization. PCR fragments of rat SP-C and CC10 were generated and cloned into the EcoRI site of the PCR2.1 vector (315 and 330 bp, respectively). Digoxigenin-labeled antisense mRNA complementary to SP-C and CC10 were produced by in vitro transcription according to the instructions of the manufacturer (Roche, Mississauga, Canada). In situ hybridization was done as described (34) .
Electron microscopy. Fragments of tumors were fixed in glutaradehyde and postfixed in osmium tetroxide for electron microscopy according to standard procedures.
Western blot analysis. Western analysis was carried out using standard protocols. Rabbit polyclonal serum directed against Grg5 was created using a COOH-terminal 18 amino acid peptide.
9 a-TLE1-specific rabbit polyclonal antiserum used in some of the experiments was the gift of Dr. Stefano Stifani (McGill University, Montreal, Quebec, Canada; ref. 35 ). Other primary antibodies were rabbit polyclonal a-TLE1 M-101, rabbit polyclonal a-ErbB1 C-20, rabbit polyclonal a-ErbB2 C-18 (Santa Cruz Biotechnology, Santa Cruz, CA), rabbit polyclonal a-Mdm2 H221 (Santa Cruz Biotechnology), mouse monoclonal a-h-galactosidase (Promega, Nepean, Canada), mouse monoclonal a-p53 Ab-1 (Calbiochem, Hornby, Canada), a-phosphoErbB2-Y1248 rabbit IgG, a-pan-Ras mouse monoclonal antibody RAS10 (Upstate Biotechnology, Lake Placid, NY), mouse monoclonal anti-h-actin (Sigma-Aldrich), mouse monoclonal a-phospho-p44/42 and rabbit polyclonal a-p44/42 (Cell Signaling, Danvers, MA). Horseradish peroxidaseconjugated secondary antibodies were purchased from Santa Cruz Biotechnology.
Transfection of NIH 3T3 cells. NIH 3T3 cells were maintained in DMEM, supplemented with 10% fetal bovine serum. Cells were grown at 37jC in a humidified atmosphere of 5% CO 2 . Standard calcium phosphatemediated transfections were carried out for 16 hours. Transfections were carried out with a total of 5 Ag DNA per well for six-well plates, using pCXGrg1-IRES-hPLAP, pCX-Mdm2 expression constructs, and pBluescript DNA. Protein lysates were collected 72 hours following transfection.
Measurement of Ras activity. Ras activity in normal lung and lung tumors was measured using a Ras activation assay kit (Upstate Biotechnology) according to the instructions of the manufacturer. The antibodies in this assay do not distinguish between H-, K-, or N-Ras.
Human lung tumor analysis. Expression of TLE1 in human lung cancer samples was analyzed using tissue microarrays. Tissue microarrays were made using the Beecher Instruments tissue microarrayer (Silver Spring, MD) according to the instructions of the manufacturer. The tissue microarrays included 71 adenocarcinomas, 46 squamous cell carcinomas, 8 large cell undifferentiated carcinomas, 3 adenosquamous carcinomas, 2 carcinoid tumors, and 1 small cell carcinoma. Immunohistochemistry was done using rabbit polyclonal a-TLE1 M-101 using the indirect peroxidaseantiperoxidase technique with 1/150 dilution following microwave treatment of the tissue microarray sections. Immunoreactivity was graded as 0 (none), 1 (slight), 2 (moderate), or 3 (strong).
Results
Transgenic mice with Cre-conditional expression of Groucho proteins. The transgene vector used for conditional Grg expression contained a loxP-flanked STOP sequence between the strong cytomegalovirus enhancer chicken h-actin promoter (36) and the Grg coding sequence (Fig. 1A) . In this configuration, the promoter drives expression of the STOP sequence, consisting of the b-geo (b-galactosidase-neomycin R ) fusion gene and three polyadenylation sequences. When Cre is introduced, the STOP sequence is excised and the Grg gene is expressed. A second reporter, the hPLAP gene, is coexpressed with Grg from an IRES. The transgenic system is designed to take advantage of tissuespecific Cre recombinase-expressing mouse lines to tailor gene expression to particular tissues. Henceforth, in this text, we refer to the transgenic mice without Cre excision as Grg1 lacZ and Grg5 lacZ and after Cre excision as Grg1 hPLAP and Grg5 hPLAP , denoting the expression of histochemical markers before and following Cre excision.
To assess the fidelity of the transgenic system, we initially crossed Grg1 lacZ and Grg5 lacZ transgenic mice with the pCX-NLSCre transgenic line (33) , which provides ubiquitous Cre excision. One mouse line each for Grg1 and Grg5 produced viable doubletransgenic offspring in a normal Mendelian ratio. Southern blot analysis showed that the transgenes had been excised globally (data not shown). Further analysis by lacZ/hPLAP staining showed the single-transgenic Grg1 and Grg5 mice had widespread lacZ expression, whereas double-transgenic Grg1/Cre and Grg5/ Cre mice had no lacZ expression but widespread hPLAP expression (Fig. 1B) . Some tissues, such as liver, displayed hPLAP but not lacZ activity, as observed previously for Z/AP and Z/EG transgenic mice (8, 32) , suggesting the h-galactosidase protein is not well expressed or tolerated in those organs. Western blot analysis showed that the hPLAP reporter activity correctly reflected Grg1 and Grg5 protein expression in the doubletransgenic mice both during embryonic development (data not shown) and in adults (Fig. 1C and D) . Sublethal expression of Grg protein was not the case with every transgenic line produced. A second Grg5 line with stronger transgene expression had an embryonic lethal phenotype when crossed to either pCX-NLS-Cre or tissue-specific Cre recombinase mice. We elected to take advantage of the sublethal expression of the lines used in this study to examine the effects of continuous, widespread Grg expression in adult animals.
Grg1 expression leads to lung adenocarcinoma. Examination of adult transgenic mice revealed that Grg1 hPLAP mice developed lung tumors with 100% penetrance (Fig. 2) . Offspring of Grg1 hPLAP mice that retain the Grg1 transgene but lack the Cre transgene have the same tumor phenotype. No tumors were observed in Grg1 lacZ mice; thus, the tumor phenotype is not associated with the transgene insertion site. The Grg5 lacZ , Grg5 hPLAP , and doubletransgenic Z/AP reporter/pCX-NLS-Cre control mice that express the hPLAP reporter but not Grg1 (8), also did not develop lung tumors. The lung neoplasms in the Grg1 hPLAP mice first appeared at 1 month as focal proliferation of tall columnar epithelial cells on preexisting alveolar septae, thus resembling early noninvasive bronchioloalveolar carcinoma (arrow; Fig. 2B and F) . At 3 to 5 months, visible tumor nodules were noted on the pleural surface ( Fig. 2C and G) . These tumors showed more extensive proliferation of these neoplastic epithelium but preserving their bronchioloalveolar growth pattern. Between 5 and 6 months, the number of lesions visible on the pleural surface increased substantially, from 3.2 F 2.2 to 8.3 F 6.0 per mouse. By 8 months, some of these lesions became confluent and appeared conspicuously as whitish solid tumor masses that are characteristic of invasive cancer. Such tumors replaced large portions of the normal lung parenchyma and showed areas of necrosis (Fig. 2E, I , and J). Our observations suggest that Grg1, but not Grg5, is able to act as a lung-specific oncogene in the mouse.
The Grg1 hPLAP lung tumors resemble human mucinous adenocarcinoma. Tumor cells were composed of tall columnar epithelial cells with basally located nuclei as well as goblet-like cells that contain periodic acid-Schiff-positive and diastase-resistant mucin in their apical cytoplasm (Fig. 2K) . Tumor cells showed a mixture of papillary, acinar, as well as bronchioloalveolar growth patterns. In addition, there was prominent extracellular mucin secretion leading to destruction of preexisting alveolar septae. The overall histopathologic findings are consistent the equivalent of human lung mucinous (colloid) adenocarcinoma. Electron microscopy of tumor samples showed that the alveoli and terminal bronchioles were lined by dysplastic epithelial cells with pleomorphic and enlarged irregularly shaped nuclei (data not shown). A high percentage of tumor cells in the Grg1 hPLAP mice stained positive for PCNA and cytokeratin but were negative for vimentin, CC10 (marker of bronchiolar Clara cells), and SP-C (marker of alveolar type II cells; refs. 32, 33), as well as for TTF-1/Nkx2.1 (data not shown). The absence of TTF-1 staining is frequently observed in human mucin-secreting pulmonary adenocarcinoma (37, 38) .
Coexpression of Grg5 with Grg1 decreases tumor burden. Grg1 hPLAP mice and Grg5 hPLAP mice were both fertile, allowing for Figure 2 . Time course of lung tumorigenesis in Grg1 hPLAP mice. A, tabular summary of lung tumor burden in Grg overexpressing mice. B, at 1 month, no lesions are visible on the pleural surface of the lung, but in serial sections (F ) small lesions can be seen that are internal to the lung (arrow ). C, at 3 months, small lesions (arrowhead ) have become visible on the pleural surface. These are small adenoma-like lesions (G ). D, at 6 months, many glassy lesions are visible on the pleural surface that show a strong bronchioalveolar growth pattern (H). By 8 months, large adenocarcinomas are visible (E ) and in some mice large regions of lung parenchyma have been replaced by tumor (I and J ). K, higher magnification shows mucin-secreting adenocarcinoma (T ) with papillary growth and destruction of preexisting alveolar architecture and stroma (S) invasion (arrow) by tumor cells, some of which show goblet cell appearance (arrowheads ). Original magnifications of microimages: F, Â100; I, Â50; J, Â16; K, Â200. hPLAP /Grg5 hPLAP double-transgenic mice. Southern blot analysis was used to confirm the inheritance of both transgenes and Western blot analysis showed that both proteins were abundantly expressed (data not shown). Aside from lung tumors, there were no additional overt phenotypic consequences associated with the coexpression of Grg1 and Grg5. We examined the lungs of 6-month-old coexpressing mice for lung tumor progression and found that lung tumor burden was reduced by the coexpression of Grg5 with Grg1 ( Figs. 2A and 3) . The percentage of mice with tumors visible on the pleural surface dropped from 96% (27 of 28 mice examined) to 50% (6 of 12 mice), whereas the average number of tumors visible on the pleural surface was reduced from 8.3 F 6.0 to 2.4 F 3.7 (P < 0.05; Fig. 2A) . In addition to the decreased number of tumors, the tumors were substantially smaller in double-transgenic Grg1/Grg5 mice ( Fig. 3A  and B) . These results suggest that the mechanism of tumorigenesis is sensitive to the ratio of long and short Grg protein isoforms.
Grg overexpression affects the tumor suppressor protein p53. The expression of proteins that are typically altered in human lung carcinogenesis was examined in Grg1-overexpressing mice. At 1 month of age, Grg1 hPLAP lung lysates showed dramatically decreased levels of p53 protein (Fig. 4A) . Other tissues examined also showed decreased p53 protein compared with control mice (data not shown). These changes were not due to direct transcriptional effects of Grg1 because Northern analysis revealed no alterations in p53 mRNA levels (Fig. 4B ).
An alternative mechanism for Grg1 reduction of p53 is through protein destabilization. Mdm2 is an E3 ubiquitin ligase that acts with HDAC1 to target p53 for proteosomal degradation. To investigate the possibility that Grg1 may collaborate with Mdm2, Grg1 and Mdm2 expression constructs were transfected into NIH3T3 cells (Fig. 4C) . Cotransfection of Mdm2 and Grg1 lead to a substantial decrease in p53 protein, whereas the same amount of Mdm2 or Grg1 alone was ineffective at reducing p53.
We noted that the p53 protein levels are also reduced in Grg5-overexpressing mice (Fig. 4D) . However, the Grg5 mice do not develop lung tumors; therefore, the reduction in p53 protein cannot solely account for the lung tumor phenotype in Grg1-overexpressing mice.
Increased ErbB1 and ErbB2 in the Grg1-overexpressing lung. At 1 month of age, we noted slightly increased levels of ErbB1 and ErbB2 in the lungs of Grg1-overexpressing mice (Fig. 4A) . In samples collected from older mice, the increase was even more pronounced (Fig. 4D) . Several observations suggest that ErbB1 and/or ErbB2 up-regulation plays a key role in Grg1-induced lung tumors. First, ErbB1 and ErbB2 were increased in the Grg1 hPLAP lung but not consistently increased in other Grg1 hPLAP tissues examined. In addition, ErbB1 and ErbB2 were not increased in Grg5 hPLAP mice, which did not develop tumors (Fig. 4D) . Finally, protein extracts from tumors consistently had even further elevated levels of ErbB2 protein compared with adjacent lung (Fig. 5A ) and higher levels of phosphorylated ErbB2 and Erk1/ Erk2 (p44/42) protein were observed in some tumors (Fig. 5A) , suggesting enhanced activation of the ErbB signaling pathway.
Altered Ras signaling in Grg1-induced tumors. Because the ErbB receptor tyrosine kinases act in part through activation of the Ras signaling pathway, we examined whether the Grg1 hPLAP lung tumors had altered Ras status. Surprisingly, Western analysis showed decreased levels of total Ras protein in tumors relative to adjacent lung (Fig. 5A) . Further measurement of total and activated GTP-bound Ras revealed that although Gg1-expressing lungs had reduced levels of total Ras, there was no change in the level of GTPbound Ras, whereas within the tumors the lower levels of total Ras were accompanied by dramatically lowered levels of activated GTP-bound Ras (Fig. 5B) . This is in stark contrast to lung tumors induced by mutant Ras in which high levels of constitutively active Ras are expressed (39) .
Groucho is overexpressed in human lung tumors. We tested the possibility that Grg1/TLE1 overexpression may contribute to lung tumorigenesis in humans by screening a tumor tissue microarray for overexpression of TLE1, the human homologue of Grg1. In normal lung, the ciliated columnar epithelial cells lining bronchial mucosa showed moderate cytoplasmic and slight or moderate nuclear immunoreactivity for TLE1 (Fig. 6A ) but endothelial cells predominantly showed strong positive nuclear staining (Fig. 6B) . Using slight to moderate immunoreactivity of the normal bronchial epithelial cells as an internal control, nuclear staining of the tumor cells was evaluated. For each tumor sample, the scores from the multiple cores were averaged and tumors demonstrating a mean staining intensity of 3 were considered as showing TLE1 overexpression. The latter was found in 5 of 46 (11%) of the squamous cell carcinomas (Fig. 6C ), 14 of 71 (20%) of the adenocarcinomas (Fig. 6D ), 1 of 8 large cell undifferentiated carcinomas, and in 1 of 3 adenosquamous carcinomas. Both carcinoid tumors and SCLC showed only moderate staining. Thus TLE1 is overexpressed in a fraction of human squamous cell carcinomas and adenocarcinomas.
Discussion
This investigation uncovered a novel oncogenic function of the long isoform of Grg1 in the lung. Mice with Grg1 overexpression develop lung adenocarcinoma that initiates at 1 month as hyperplastic lesions resembling atypical adenomatous hyperplasia, the precursor lesion of lung adenocarcinoma in humans (7, 40) . Grg5 hPLAP mice do not develop tumors and coexpression of Grg5 with Grg1 is able to lessen the tumor burden induced by Grg1 overexpression. Mechanistically, this suggests that deregulated expression of long Grg isoforms contributes to lung neoplasia and confirms in an in vivo context that short isoforms can act in a dominant negative fashion to partially inhibit the tumor phenotype.
In examining the basis for the oncogenic effect of Grg1, we found that the level of the p53 tumor suppressor is dramatically decreased by Grg1 overexpression. The altered status of p53 protein in Grg1 hPLAP mice may contribute to malignancy. However, a similar decrease in p53 was observed in Grg5 hPLAP mice, suggesting a function shared by long and short Groucho isoforms and demonstrating that lower p53 levels are not solely responsible for the lung tumor phenotype of Grg1 mice. The decrease in p53 is likely a result of posttranslational regulation, as p53 transcript levels are not changed in Grg-overexpressing mice. The p53 protein is subject to numerous posttranslational modifications, including phosphorylation, acetylation, ubiquitination, and sumoylation (41) . A possible mechanism for Grg regulation of p53 is through recruitment into HDAC1/Mdm2/p53-containing complexes. It is established that HDAC1 and Mdm2 deacetylate and ubiquitylate p53 on lysine residues, which targets p53 for degradation in the proteosome (42) (43) (44) . As Groucho proteins directly bind with HDAC to deacetylate histone proteins (11, 26) , Grg1 may also be part of the HDAC1 complex that deacetylates p53. This would represent a novel role for Groucho proteins in posttranslational regulation of nonhistone proteins. Grg5 would not be predicted to directly recruit HDAC activity; however, because Grg proteins function as a tetramer (22) , Grg5 may form complexes with full-length Grg isoforms. Overall, the results suggest the effect of Grg overexpression on the p53 pathway is mediated by a posttranslational mechanism.
In the Grg1 hPLAP lung, secondary genetic or epigenetic alterations must act coordinately with overexpressed Grg1, as the majority of Grg1-overexpressing lung epithelium cells do not become malignant. Grg1, but not Grg5, overexpression results in elevated levels of ErbB1 and ErbB2. This deregulation may predispose the Grg1 lung to tumorigenesis. Higher overall levels and phosphorylation of the ErbB2 receptor tyrosine kinase were noted in the Grg1-induced lung tumors, suggesting that ErbB2 may be a key growth regulator for these tumors. Abnormal ErbB2 expression has been reported in f35% of human lung adenocarcinoma (45) .
If ErbB receptor activation does mediate proliferation and/or survival in Grg1-induced tumors, it must be acting through pathways that do not activate Ras. Although mutation of K-ras occurs in a significant number of human lung adenocarcinomas (39) , overactivation of Ras does not seem to be one of the cooperating events in Grg1-induced tumorigenesis. On the contrary, the lung tumors have decreased levels of GTP-bound Ras. Ras alleles that have been activated through mutation are often called dominant oncogenes as they are sufficient to transform transfected cells and induce tumor formation in vivo. However, evidence suggests that the dominance of activating Ras mutations depends on high levels of overexpression of mutant Ras (46) and loss of wild-type alleles. For example, heterozygosity for a null allele at the K-ras locus increases urethane-induced tumor susceptibility in the lung, whereas wild-type K-ras overexpression limits growth of lung tumor cells in nude mice (47) . This suggests that wild-type K-ras has an antitumor role even in the presence of the activated allele. A decrease in wild-type Ras activation in Grg1-induced tumors may, therefore, be a contributing factor to growth of these malignancies. These mice may prove a valuable mouse model of lung tumorigenesis that is independent of hyperactive Ras signaling and the mucinous type lung adenocarcinoma.
In summary, we have shown the in vivo oncogenic potential of overexpressing a full-length Groucho protein, Grg1. Although Grg1 overexpression negatively affects the tumor suppressor p53, this alone cannot account for the tumor phenotype of Grg1, as Grg5 also decreases the level of p53 protein but is nontransforming in the mouse lung. Increased ErbB1 and ErbB2 may be key factors in Grg1-induced lung tumors. Importantly, Grg1 overexpression may contribute to a subset of human NSCLCs as it is overexpressed in 11% of squamous cell carcinomas and 20% of adenocarcinomas.
